Get started
Author

Ruthanna C. Davi

Observed name: Ruthanna Davi
ORCID: 0000-0003-2650-5384
Observed ORCID: 0000-0003-2650-5384
OpenAlex ID: A5016836505
Real-World Data as External Controls: Practical Experience from Notable Marketing Applications of New Therapies
2022 · Rima Izem, Joan Buenconsejo, et al. · Therapeutic Innovation & Regulatory Science · 25
Exploring the Potential of External Control Arms created from Patient Level Data: A case study in non-small cell lung cancer
2022 · Xiang Yin, Pallavi S. Mishra-Kalyan, et al. · Journal of Biopharmaceutical Statistics · 20
Historic Clinical Trial External Control Arm Provides Actionable GEN-1 Efficacy Estimate Before a Randomized Trial
2023 · Xiang Yin, Ruthanna Davi, et al. · JCO Clinical Cancer Informatics · 13
Building an External Control Arm for Development of a New Molecular Entity: An Application in a Recurrent Glioblastoma Trial for MDNA55
2022 · Antara Majumdar, Ruthanna Davi, et al. · Statistics in Biosciences · 9
Clrm-09. Incorporating External Control Arm in Mdna55 Recurrent Glioblastoma Registration Trial
2021 · Ruthanna Davi, Antara Majumdar, et al. · Neuro-Oncology Advances · 6
Outcomes of patients aged ≥26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials
2024 · Monique C. Minnema, Xiang Yin, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 5
The Validity of a Synthetic Control Arm Derived from Historical Multiple Myeloma Clinical Trials
2023 · Xiang Yin, Elizabeth Stuart, et al. · Blood · 3
Plitidepsin in combination with dexamethasone (ADMYRE trial) versus an external control arm of pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma
2026 · Heinz Ludwig, Evangelos Terpos, et al. · Annals of Hematology · 1
PDF
Assessing the relationship in relapsed-refractory multiple myeloma between response, progression, and survival between pooled clinical trial subjects and a real-world electronic medical record data source.
2020 · Mark Layton Watson, Charlie Hurmiz, et al. · Journal of Clinical Oncology · 1
Estimating Relationships between Response, Progression, and Survival in Relapsed-Refractory Multiple Myeloma in Pooled Clinical Trials Database
2019 · Aaron Galaznik, Emelly Rusli, et al. · Blood · 1
Comments on the Salmeterol Multicenter Asthma Research Trial
2006 · Sally M. Seymour, Eugene J. Sullivan, et al. · CHEST Journal · 1
PDF
Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia
2026 · Max S. Topp, Bijal D. Shah, et al. · Leukemia
PDF
Reproducing comparative therapeutic efficacy in relapsed refractory multiple myeloma using an external control arm derived from historical clinical trial data
2026 · Xiang Yin, Mehmet Burcu, et al. · Research Square
PDF
Rwd154 External Control Arm Feasibility Across External Data Sources in Oncology: Methodological and Regulatory Science Considerations
2026 · Bernat Navarro, Kawther Abdilleh, et al. · Value in Health
A Cautionary Note on E-Values Using Biased Risk Ratio Approximations from Hazard Ratios
2026 · Thomas Gwise, Debashis Ghosh, et al. · Statistics in Biopharmaceutical Research
Comparison of Obecabtagene Autoleucel (obe-cel) Versus an External Control Arm (ECA) in Adult Patients (pts) with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
2025 · Max S Topp, Bijal D Shah, et al. · Transplantation and Cellular Therapy
Assessing the impact of unmeasured confounding in external control arms via tipping point analyses.
2024 · Xiang Yin, Elizabeth Stuart, et al. · Journal of Clinical Oncology
PDF
Abstract PO1-05-12: Pooled clinical trial data analyses comparing the biology of HER2-low vs HER2-0 breast cancer in patients with metastatic breast cancer following treatment with standard single agent chemotherapy
2024 · Elizabeth Lamont, Emily Stein, et al. · Cancer Research
Bios-01. Efficacy Among Therapeutically Effective Absorbed Dose Patients in Respect-gbm Phase I of Rhenium-186 Nanoliposome (186rnl) in Recurrent Glioblastoma (rgbm) Compared to an External Control Arm (eca)
2023 · Lisa Ensign, Norman LaFrance, et al. · Neuro-Oncology
PDF
Clinical characterization of patients with recurrent glioblastoma in trials involving CED and non-CED treatment.
2023 · Lisa G. Ensign, Denis Boisvert, et al. · Journal of Clinical Oncology
Overview of the Current Real-World Evidence Regulatory Landscape
2023 · Rima Izem, Ruthanna Davi, et al. · Springer eBooks
Abstract 1025: Phase Ib trial single-arm efficacy estimates via comparison to a historical clinical trial synthetic control arm
2022 · Xiang Yin, Ruthanna Davi, et al. · Cancer Research
Works count: 22
Citation count: 85
H-index: 5
I10-index: 3
Year
Topic
Type